Tirzepatide Research: SURPASS, SURMOUNT, and the Full Clinical Record

The short version

The tirzepatide research programme spans from 2018 discovery chemistry to more than a dozen phase 3 randomized controlled trials covering type 2 diabetes, obesity, sleep apnea, liver disease, and heart failure. The key findings: it activates two gut hormone receptors (GIP and GLP-1) with a single molecule; it produces greater glycemic control and weight reduction than semaglutide in head-to-head trials in both diabetic and non-diabetic populations; it reduces the apnea-hypopnea index in sleep apnea; and early liver data from the SYNERGY-NASH trial show benefit in a liver disease (steatohepatitis) with few approved treatments. The evidence base is large, largely sponsor-funded, and well-documented.

Tirzepatide mechanism of action: dual incretin signalling

Tirzepatide's pharmacological identity is as an imbalanced, biased dual GIP and GLP-1 receptor agonist ^[2]. Imbalanced means it engages the GIP receptor more fully than the GLP-1 receptor. Biased means its activation of the GLP-1 receptor preferentially engages cyclic AMP (cAMP) signalling pathways over beta-arrestin recruitment — a mode of receptor activation that may enhance insulin secretion by avoiding some of the desensitization that follows conventional GLP-1R agonism ^[2].

At the system level, engaging both receptors simultaneously amplifies the meal-stimulated incretin effect: GIP receptor activation enhances insulin secretion through pathways complementary to GLP-1R signalling, while GLP-1R activation suppresses glucagon, delays gastric emptying, and reduces appetite through central nervous system circuits ^[1][7]. In chronic mouse administration, tirzepatide reduced body weight and food intake significantly more than a selective GLP-1 receptor agonist — the first evidence that dual agonism adds effect beyond GLP-1 alone ^[1]. A phase 1 programme in 142 subjects confirmed once-weekly PK and reduced fasting glucose and body weight versus placebo ^[1].

The SURPASS programme: type 2 diabetes

The SURPASS programme is a set of phase 3 trials in adults with type 2 diabetes. Core findings:

SURPASS-2 (40 weeks, 1,879 adults with type 2 diabetes, open-label head-to-head against semaglutide 1 mg): tirzepatide reduced HbA1c by 2.01, 2.24, and 2.30 percentage points at 5, 10, and 15 mg versus 1.86 percentage points with semaglutide 1 mg. Tirzepatide was noninferior and superior at all three doses. Weight treatment differences were -1.9, -3.6, and -5.5 kg in favour of tirzepatide ^[3].

A 2026 systematic review and meta-analysis compared tirzepatide specifically to dulaglutide across three trials and found tirzepatide's greater efficacy came with a tolerability trade-off: discontinuation due to adverse events was roughly 32% higher with tirzepatide, driven by gastrointestinal effects, and the glycemic benefit was less pronounced in long-standing diabetes with established cardiovascular disease than in earlier-stage disease ^[6].

A pooled SURPASS analysis in older adults found hypoglycemia incidence consistent with the overall trial population regardless of background insulin or sulfonylurea use — with the caveat that concomitant use of these agents does raise hypoglycemia risk ^[33].

The SURMOUNT programme: obesity and overweight

The SURMOUNT programme comprises trials in adults with obesity or overweight without type 2 diabetes, generating the most detailed weight-efficacy data in the drug's clinical history:

SURMOUNT-1 (72 weeks, 2,539 adults): mean weight changes -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) versus -3.1% placebo. At least 20% weight loss achieved by 50% of the 15 mg group ^[4].

SURMOUNT-5 (72 weeks, 751 adults, head-to-head versus semaglutide): -20.2% versus -13.7% (P<0.001). Tirzepatide superior across all weight-loss thresholds ^[5].

SURMOUNT-J (72 weeks, Japanese population, mITT n=225 excluding diabetes): -16.1% (10 mg) and -21.1% (15 mg) versus placebo; 94-96% achieved at least 5% weight loss ^[9].

A 2026 post hoc analysis of SURMOUNT-1 (n=1,605) found progressive cardiometabolic improvements tracked with weight loss: systolic blood pressure, waist circumference, HOMA-IR (insulin resistance marker), HbA1c, and lipid parameters all improved in proportion to the percentage of weight lost. Improvements in insulin resistance and HbA1c were detectable from the smallest weight-loss category; lipid improvements emerged primarily after at least 10% weight reduction ^[15].

A 2026 post hoc analysis of SURMOUNT-1, -3, and -4 found that roughly one-fifth of participants were on weight-inducing medications at baseline; tirzepatide produced comparable percentage weight change in that subgroup versus the full trial population (e.g., -13.3% to -21.3% at week 72 in SURMOUNT-1 depending on dose), suggesting concomitant use of weight-promoting medications does not meaningfully attenuate efficacy ^[16].

Tirzepatide vs semaglutide

Two head-to-head trials have compared tirzepatide directly to semaglutide:

1. SURPASS-2 (type 2 diabetes, 40 weeks, open-label): tirzepatide superior to semaglutide 1 mg on HbA1c and weight at all three tested doses ^[3].
2. SURMOUNT-5 (obesity without diabetes, 72 weeks, open-label): tirzepatide at maximum tolerated dose (10 or 15 mg) produced -20.2% weight loss versus -13.7% with semaglutide at maximum tolerated dose (1.7 or 2.4 mg); tirzepatide superior ^[5].

A 2024 network meta-analysis of 31 RCTs (n>35,000) ranked tirzepatide 15 mg in the top three across weight-related parameters, glycemic profile, lipid parameters, and blood pressure, and found it had the highest efficacy for achieving at least 15% weight loss versus placebo (risk ratio 10.24, 95% CI 6.42-16.34) ^[8].

Both head-to-head trials are open-label, which is a methodological limitation for patient-reported outcomes, though objective weight is less susceptible to unblinding bias.

Expanding indications: sleep apnea, liver disease, heart failure

Beyond glucose control and weight management, the clinical programme has produced evidence across three additional indications:

Obstructive sleep apnea (SURMOUNT-OSA): a phase 3 trial in adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide reduced the apnea-hypopnea index (the count of breathing interruptions per hour of sleep, used to grade sleep apnea severity) by approximately 27-30 events per hour versus a modest change with placebo; the FDA approved tirzepatide for this indication ^[12].

Metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH): a phase 2b trial in adults with MASH (formerly called NASH — a progressive fatty liver disease characterized by inflammation and fibrosis) found tirzepatide associated with histological resolution and fibrosis improvement; data published in NEJM 2024 ^[14].

Heart failure with preserved ejection fraction (SUMMIT): a phase 3 trial in adults with HFpEF (heart failure in which the heart's pumping fraction remains normal) and obesity found tirzepatide improved exercise function and heart failure symptoms; published in NEJM 2025 ^[13].

These indications share obesity-mediated pathophysiology, suggesting weight reduction may be a common mechanism of benefit, though the trials were not designed to separate the effects of weight loss from any direct drug action.

Recent findings: 2024-2026

Recent studies from 2024-2026 have extended the evidence base:

A 2025 post hoc SURMOUNT-1 cardiometabolic analysis (n=1,605) found that participants losing at least 35% of body weight had systolic BP reductions of -14.2 mmHg, waist circumference reductions of -32.4 cm, and HOMA-IR reductions of -59.7% ^[15].

A 2026 JAMA Netw Open analysis of SURMOUNT-1, -3, and -4 found tirzepatide produced comparable percentage weight change in participants on weight-inducing medications (-13.3% to -21.3% at week 72 in SURMOUNT-1) as in the full trial population, suggesting the drug is effective even against a background of medications that promote weight gain ^[16].

A 2026 phase 3 trial in Chinese patients with early type 2 diabetes (SURPASS-CN-MONO, n not published; data to week 40) found HbA1c treatment differences versus placebo of approximately -2.0 percentage points at all three doses (5, 10, 15 mg), with body-weight reductions of -6.0, -6.1, and -9.7 kg, confirming efficacy and safety in a Chinese population ^[16].